These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31501043)

  • 21. Guidelines impact cholesterol management.
    Yu S; Zolfaghari K; Rascati KL; Copeland LA; Godley PJ; McNeal C
    J Clin Lipidol; 2019; 13(3):432-442. PubMed ID: 30992244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system.
    Ahmed ST; Mahtta D; Rehman H; Akeroyd J; Al Rifai M; Rodriguez F; Jneid H; Nasir K; Samad Z; Alam M; Petersen LA; Virani SS
    Am Heart J; 2020 Mar; 221():9-18. PubMed ID: 31896038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines.
    Virani SS; Woodard LD; Akeroyd JM; Ramsey DJ; Ballantyne CM; Petersen LA
    Clin Cardiol; 2014 Nov; 37(11):653-9. PubMed ID: 25324147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan.
    Yeh YT; Yin WH; Tseng WK; Lin FJ; Yeh HI; Chen JW; Wu YW; Wu CC;
    PLoS One; 2017; 12(10):e0186861. PubMed ID: 29073192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry.
    Nanna MG; Navar AM; Wang TY; Li S; Virani SS; Li Z; Robinson JG; Roger VL; Wilson PWF; Goldberg AC; Koren A; Louie MJ; Peterson ED
    Am Heart J; 2019 Aug; 214():113-124. PubMed ID: 31202098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between statin adherence and cholesterol level reduction from baseline in a veteran population.
    Kazerooni R; Watanabe JH; Bounthavong M
    Pharmacotherapy; 2013 Oct; 33(10):1044-52. PubMed ID: 23744794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.
    Chamberlain AM; Cohen SS; Weston SA; Fox KM; Xiang P; Killian JM; Qian Y
    Am J Cardiol; 2019 Jun; 123(11):1739-1744. PubMed ID: 30948001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dl from the Veterans Affairs Health System.
    Rodriguez F; Knowles JW; Maron DJ; Virani SS; Heidenreich PA
    Am J Cardiol; 2018 Sep; 122(5):756-761. PubMed ID: 30055758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients.
    Braet DJ; Pourak K; Mouli V; Palmon I; Dinh D; Osborne NH; Vemuri C; Brandt EJ
    Vascular; 2024 Feb; 32(1):210-219. PubMed ID: 36113420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System.
    Vassy JL; Lu B; Ho YL; Galloway A; Raghavan S; Honerlaw J; Tarko L; Russo J; Qazi S; Orkaby AR; Tanukonda V; Djousse L; Gaziano JM; Gagnon DR; Cho K; Wilson PWF
    JAMA Netw Open; 2020 Jul; 3(7):e208236. PubMed ID: 32662843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.